SynthesisHypertension research : official journal of the Japanese Society of Hypertension2023
Endocan as a marker of endothelial dysfunction in hypertension: a systematic review and meta-analysis.
Synthesis in Hypertension research : official journal of the Japanese Society of Hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- The predictive value of endocan as a novel biomarker: an umbrella study on meta-analyses.Systematic reviews · 2025Pooled it
- Serum Endocan as a Novel Biomarker of Cerebral Ischemia-Reperfusion Injury in a Rat Model.Biomedicines · 2026Article
- Current Landscape of the Interrelationship Between Periodontitis, Type 2 Diabetes Mellitus, and COVID-19.International journal of molecular sciences · 2025Review
- Mrc1 (MMR, CD206) controls the blood proteome in reducing inflammation, age-associated organ dysfunction and mortality in sepsis.Nature communications · 2025Article
- Association of plasma endocan levels with metabolic parameters and predictive value of endocan for the development of complications in patients with type 2 diabetes mellitus: An observational study.Biomolecules & biomedicine · 2025Observational
- Serum Endocan Levels as a Risk Factor for Peripheral Artery Disease in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5.Medicina (Kaunas, Lithuania) · 2025Article
- Endocan as a marker of endotheliitis in COVID-19 patients: modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Endothelial MicroRNA-214 Confers Angiotensin II Hypertension by Targeting eNOS in Mice.Kidney & blood pressure research · 2025Article
- Soluble endoglin reflects endothelial dysfunction in myocardial infarction patients: a retrospective observational study.International journal of medical sciences · 2025Observational
- A vascular endothelial cell, neuron, and microglia tri-culture model to study hypertension-related depression.Frontiers in cellular neuroscience · 2025Article
- Current topic of vascular function in hypertension in 2023-2024.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Endocan as a biomarker for acute respiratory distress syndrome: A systematic review and meta-analysis.Health science reports · 2024Review
- How can endocan be used as a specific biomarker of endothelial dysfunction in hypertension?Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Endocan may predict the presence of coronary slow flow and coronary artery disease.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Association between serum endocan levels and organ failure in hospitalized patients with cirrhosis.PloS one · 2024Article
- Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome.Life (Basel, Switzerland) · 2023Review
- Soluble Proteoglycans and Proteoglycan Fragments as Biomarkers of Pathological Extracellular Matrix Remodeling.Proteoglycan researchReview
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is one of the foremost risk factors for cardiovascular disease and a significant cause of death worldwide. Importantly, endothelial dysfunction (ED) is one of the primary manifestations that may precede the development of hypertension. Endocan is a novel endothelial dysfunction and inflammation biomarker secreted from endothelial cells. Whether endocan may serve as a biomarker of hypertension is currently debated. This systematic review and meta-analysis aimed at linking endocan to ED in hypertensive patients. International databases, including PubMed, Scopus, Embase, and Web of Science, were systematically searched for studies investigating Endocan serum or plasma levels in hypertensive patients and healthy controls. Random effect meta-analysis was performed to calculate the standardized mean difference (SMD) and 95% confidence interval (CI). A total of 20 studies assessing the association between endocan levels and hypertension were included in which 3130 individuals with a mean age of 50.48 ± 8.45 years were assessed. Hypertensive patients presented with higher circulating endocan levels (SMD 0.91, 95% CI 0.44-1.38, p-value < 0.01) compared with healthy controls. Interestingly, our data demonstrated that removing three studies assessing endocan levels in hypertensive patients with different comorbidities or special populations resulted in the same statistically higher endocan levels (SMD 1.16, 95% CI 0.66-1.65, p-value < 0.01). Overall, this systematic review and meta-analysis indicated that in hypertensive patients circulating endocan levels are significantly elevated. Thus, suggesting endocan as an easy-to-use biomarker to detect ED in hypertension. Despite this, more research is warranted to address this potential ability specifically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.